In this section
-
About LHBD
On this page
Quick links
Related links
External links
About LHBD
The Laboratory for
Human Brain Dynamics (LHBD, division of AAI Scientific
Cultural Services Ltd.),
was established and managed by Prof Andreas A Ioannides, who is a
neuroscientist with physics background. He had worked as a team leader
in world renowned research centers in UK, Germany and Japan. Since
2009, he has set up a new team in Cyprus, continuing some of the basic
neuroscience work that started in Japan and building a multimodal
approach to the exquisite MEG/EEG capabilities. His present research
emphasis is on the translation of basic research results, often
obtained with the most sophisticated and expensive equipments, to
personalized health monitoring and clinical applications with
inexpensive and widely available devices.
LHBD conducts neuroscience research, some supported internally and some by scientific grants. LHBD also provides a wide range of services to research and medical organizations. We work with number of leading research centres across the globe and are always looking to expand and deepen our collaborative efforts. We are also always open to new and interesting collaborations where a combination of expertise may be mutually beneficial.
The general research areas that we are currently interested in are described below. We are open to collaborations in these and related fields. If you are interested in either a collaboration or using our services please contact us.
Basic neuroscience research using MEG
We conduct magnetoencephalography (MEG) research using mostly our own software developed over the last 30 years. The software offers sophisticated and highly specialized applications, focusing on data mining of single trial MEG signals and especially tomographic solutions extracted from MEG data. In the last few years we use increasingly other open source packages because thesepackages have become sufficiently sophisticated and we would maintain continuity in our collaborations with partners abroad. We continue the analysis of the unique set of MEG data collected in the first 10 years of the millennium at RIKEN BSI. As time goes by we add new MEG data collected as part of collaborations with colleagues in Europe and North America. The analysis of these data invariably benefits from the availability of the earlier data collected in Japan. We are planning new experiments and are open to new collaborations in the areas that we have already published extensively and in other areas that are either likely to provide key insights about normal brain function or contribute to clinical practice. We are particularly keen to apply our techniques to cases where the combination of accurate localization (within a few millimetres) and precise timing (within a few milliseconds) are essential.
EEG measurements and analysis
We support and develop electroencephalography (EEG) measurements and analysis methods for neuroscience, clinical and other applications (e.g. continuous patient monitoring, man-machine interface, etc.). In neuroscience research, we are exploring the limits of localization that high density EEG can deliver by contrasting widely-available established methods with methods that are adapted for EEG, using the algorithms we have developed in the last 20 years for MEG. At a more applications oriented end, we are exploring the optimization of few channel EEG and other body monitoring devices. We are particularly interested in the development of few channel and wearable EEG devices for real-time performance evaluation and continuous independent patient care applications. Almost all of our recent studies have in one way or another advanced the measurement and analysis of EEG data, but we are not publishing most of these results until we complete our effort to protect the intellectual property rights of the related work.
Translational/Clinical research
We are collaborating with clinicians for developing diagnostic biomarkers based on EEG and/or MEG measurements. We are also developing fast, effective and reliable methods for the evaluation of pharmaceuticals in collaboration with overseas partners.